Vincristine sulfate

Catalog No.S1241 Synonyms: Leurocristine

Vincristine sulfate Chemical Structure

Molecular Weight(MW): 923.04

Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.

Size Price Stock Quantity  
USD 70 In stock
USD 270 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 34 Publications

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.
Targets
Microtubules [1]
(Cell-free assay)
32 μM
In vitro

Vincristine inhibits net addition of tubulin dimers at assembly ends of steady-state microtubules with Ki of 85 nM. [1] At low concentrations, Vincristine stabilizes the spindle apparatus resulting in failure of the chromosomes to segregate leading to metaphase arrest and inhibition of mitosis. At higher concentrations, Vincristine may disrupt and induce total depolymerization of microtubules. [2] Vincristine induces apoptosis in tumor cells and inhibits SH-SY5Y cell proliferation with IC50 of 0.1 μM. Vincristine induces mitotic arrest and promots the expression of caspase-3 and -9 and cyclin B, while decreasing the expression of cyclin D. [4] Vincristine induced neurotoxicity is caused by interference with microtubule function, which results in blockage of axonal transport and thus in axonal degeneration. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HepG2.2.15 NV\Sc5VYS2WubDDWbYFjcWyrdImgRZN{[Xl? M3f5WFAuOC53IN88US=> MXuyOEBp M2XEUoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NF:3Z4MzPTZ4M{e2PS=>
HepG2-HBV1.1 MVzBdI9xfG:|aYOgRZN{[Xl? MXiwMVAvPSEQvF2= NEHmVpAzPCCq NUS5enZZcW6mdXPld{BieG:ydH;zbZMh\G:|ZTDk[ZBmdmSnboTsfS=> M17kPFI2PjZ|N{[5
HepG2.2.15 M1LVVmZ2dmO2aX;uJGF{e2G7 M{D5ZlAvOSEQvF2= NFixSJUzPCCq NYW2RnBHeHKxbX;0[ZMhcGWyYYTpeIl{KEJidnnyeZMheHKxdHXpckBmgHC{ZYPzbY9v MmXYNlU3PjN5Nkm=
HepG2-HBV1.1 MVnGeY5kfGmxbjDBd5NigQ>? NIf2fFgxNjFizszN Ml\3NlQhcA>? MV3wdo9ud3SnczDo[ZBifGm2aYOgRkB3cXK3czDwdo91\WmwIHX4dJJme3Orb36= M3zyTlI2PjZ|N{[5
HepG2-HBV1.1 MYPGeY5kfGmxbjDBd5NigQ>? NGrvZXUxNjFizszN MWS0PEBp NG[ye|Zxem:vb4Tld{Bk\WyuIHX4Z5JmfGmxbjDv[kBp\XCjdHn0bZMhSiC4aYL1d{BvfWOuZX;jZZB{cWS|IHnud5Rm[WRib3[gbIVx[XSrdHnzJGIhfmm{dYOgSIFv\SCyYYL0bYNt\XN? NX3Xd5VoOjV4NkO3Olk>
HepG2-HBV1.1 MkPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fjclAvOSEQvF2= MYSxMVUh\A>? M2n2cIlvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJJRqdWViZHXw[Y5l\W62bIm= NVzydIJtOjV4NkO3Olk>
HepG2-HBV1.1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jwNlAvOSEQvF2= MVuxMVUh\A>? NXTMSopwcW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hfGmvZTDk[ZBmdmSnboTsfS=> NIj1e|czPTZ4M{e2PS=>
HepG2-HBV1.1 M13ySWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjQPHQzOC5zIN88US=> M1rJUVEzNTd{IHi= Ml7ubY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDheEBUNXCqYYPl NGPSd5ozPTZ4M{e2PS=>
HepG2-HBV1.1 NFnYeWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LCWlAvOSEQvF2= NWrjdpY1OTJvN{KgbC=> MnnpbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDheEBUNXCqYYPl M3rkZ|I2PjZ|N{[5
Raji NVnRdWRYTnWwY4Tpc44hSXO|YYm= Ml7DNE42yqEQvF2= MkPaO|IhcA>? M4\pToFjd2yrc3jld{BifXSxcHjh[5nDqA>? MmTBNlU1PDZ|N{e=
SK-MEL-28  M3HEfWZ2dmO2aX;uJGF{e2G7 M3PwVlMxKG6P NFrTNVk3KGh? NF2xZplqdmS3Y3XzJGcz6oDVTTDj[YxtNWO7Y3zlJIFzemW|dB?= M3PTblI2OzF|MEGw
H157 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUOyW|NkUUN3ME2xMlA{KMLzIECuNFQhdWm3Ml2= NXHj[2RHOjV{NUe5NVE>
Jurkat MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYSxMVMhdk1? MlfOOFjDqGh? NVPJTpV3TE2VTx?= M2OyToRm[3KnYYPld{B3cWGkbHWgZ4VtdCCwdX3i[ZJ{KGSxc3Wg[IVx\W6mZX70cJk> MVuyOVE2PjF2Nh?=
CEM MknxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TDW|EuOyCwTR?= Ml:zOFjDqGh? MUfEUXNQ NVm5fGFo\GWlcnXhd4V{KH[rYXLs[UBk\WyuIH71cYJmenNiZH;z[UBl\XCnbnTlcpRtgQ>? MVuyOVE2PjF2Nh?=
P12 M2D3OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLUVIFqOS1|IH7N MYm0POKhcA>? M2\jbmROW09? NELCS3ll\WO{ZXHz[ZMhfmmjYnzlJINmdGxiboXtZoVzeyCmb4PlJIRmeGWwZHXueIx6 MUWyOVE2PjF2Nh?=
KB NInQWZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DmPWlEPTB;MD6wNFQ6KMLzIECuNFAxOSEQvF2= NHK4bVYzPTB3OEWyOi=>
KBv200 (ABCB1) MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofKTWM2OD1yLkO0OlIhyrFiMD6wNFY3KM7:TR?= MoPpNlUxPTh3Mk[=
SUDHL6  Mnv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVmx5qCK|ryP NVGzTpQ4PDhxN{KgbC=> M1zUZolvcGmkaYTzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk> MV2yOFk3OTZyNB?=
SUDHL6  MkTySpVv[3Srb36gRZN{[Xl? NGrEO2Qy6oDLzszN MlP4O|IhcA>? NULFSYdZcW6mdXPld{B{cWewaX\pZ4FvfCCjcH;weI91cWNibX;ydIhwdG:peTDjbIFv\2W|IHPveJJme3SnZDD3bZRpKEKFTEGxRUB{cVKQQR?= MX2yOFk3OTZyNB?=
HCT-116 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rYZ2dKPTB;NTDuUS=> NULuWJBmOjR7Mke4OVc>
SKNBe2C NIftUIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\Nb29KSzVyPUOyMljDuTRwMDDuUS=> MonXNlQ6OjF7MkC=
IGNR91 NETB[49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXtTWM2OD1{ND6zxtEyNjdibl2= MVGyOFkzOTl{MB?=
SKNAS NXH1fXNbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXS3VVRGUUN3ME2xMlXDuTBwMjDuUS=> NVXvOpRqOjR7MkG5NlA>
LAN1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmX5TWM2OD1{LkRCtVAvOiCwTR?= NVXTXIFROjR7MkG5NlA>
SHSY5Y MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRThwMtMxNE43KG6P NFH5UnYzPDl{MUmyNC=>
A549-WT M13hRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTF7LkSzO{DDuSByLkW5OEAhdk1? MXeyOFg2QDh{Nx?=
A549-R MmWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTF{LkG3PEDDuSByLkOzN{Ahdk1? M{D2NVI1QDV6OEK3
MCF-7-WT NHjZ[WpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPlfFNEUUN3ME2xO{44PTJiwsGgNE4zOThiIH7N NVXLTmJJOjR6NUi4Nlc>
MCF-7-R MmrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTVwNUO5JOKyKDBwMUS0JEBvVQ>? MX[yOFg2QDh{Nx?=
A549-R NVjiVmN1S3m2b4TvfIlkcXS7IFHzd4F6 NVX5S5BDUUN3ME2xNk4yPzhiwsGgNE4{OzNibl2= MX6yOFg2QDh{Nx?=
MCF-7-R MUjDfZRwfG:6aXPpeJkhSXO|YYm= MX;JR|UxRTVwNUO5JOKyKDBwMUS0JI5O NHvQfIUzPDh3OEiyOy=>
SW620 MkDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVi2NFJuUUN3ME23MlgxKMLzIECuNFghdk1? NUPOR4J3OjR5Mk[3N|k>
SW620/AD300 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTlyOT62NEDDuSB6LkmxJI5O MUCyOFczPjd|OR?=
HEK293/pcDNA3.1 M3Hv[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\ETWM2OD1zLkS1JOKyKDBwMkCgcm0> NEXKUHUzPDd{NkezPS=>
HEK293/ABCC1 MmPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTF7LkK5JOKyKDJwMEigcm0> MkXBNlQ4OjZ5M{m=
TCC MkDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPFVohEOjRiaB?= NE\BSZNKSzVyPUewJI5O M{XXPFI1PzF4OUS0
TCC MmraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPIdVkzPDhiaB?= MojFTWM2OD13MDDuUS=> NGSz[m4zPDdzNkm0OC=>
HepG2/ADM M2PKd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTJwN{i2N:KyOC5{M{exJO69VQ>? MVeyOFcxPDV3Nh?=
HepG2 NXTaZpoyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn[wTWM2OD1yLkCxNVXDuTBwMECxO{DPxE1? NULMPHFkOjR5MES1OVY>
MCF-7/ADR NVLYOHRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEP6Z4VKSzVyPUSuOFgzPsLzMD6yNFcxKM7:TR?= MkXUNlQ4ODR3NU[=
MCF-7 NGnzcpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\STWM2OD1yLkCxOVnDuTBwMEC2NkDPxE1? NED3W4MzPDdyNEW1Oi=>
A-172  MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLDTncxNjIEoN88US=> NWO3PIh2OjRxN{KgbC=> M{HVZolvcGmkaYTzJINmdGxiZ4Lve5RpKHSrbXWg[IVx\W6mZX70cJk> MWKyOFU{ODJ|NR?=
U-251MG M4fMR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXmwMlHDqM7:TR?= MoTkNlQwPzJiaB?= M4D2SIlvcGmkaYTzJINmdGxiZ4Lve5RpKHSrbXWg[IVx\W6mZX70cJk> M2nF[|I1PTNyMkO1
DLD-1 MXzGeY5kfGmxbjDBd5NigQ>? MlPyNVAxKG6P M{fabFQ5KGh? MWLwdo9ud3SnczDSWW5ZOyCmZX3leIh6dGG2aX;uxsA> Ml:zNlQ1ODN2NUO=
CCD18Co NV\pR2J5TnWwY4Tpc44hSXO|YYm= M1\acVExOCCwTR?= M1zLeVQ5KGh? NXfidnNNeHKxbX;0[ZMhWlWQWEOg[IVu\XSqeXzheIlwdsLi NFe4eFczPDRyM{S1Ny=>
DLD-1 MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HWWFAuOTByMDDuUS=> NV\vOZlxPDhiaB?= NWPTPGtQcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? M4T5dlI1PDB|NEWz
CCD18Co MnezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnNe5kxNTFyMECgcm0> MkiyOFghcA>? MV3pcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NHnuZW8zPDRyM{S1Ny=>
HepG2 NWXYfmQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHvNlQhcA>? MoOxTWM2OD13Mj615qCK|ryP M2rLZVI1OzRzNki4
HEK293/pcDNA3.1 M3TCW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPnTXJrUUN3ME2wMlAxPMLzMD6wNFA{KM7:TR?= NWDUZ4lOOjR{OES3PFM>
HEK293/MRP1 Mn;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoWyTWM2OD1yLkC1OeKyOC5yMUKwJO69VQ>? MU[yOFI5PDd6Mx?=
Ramos NF7MU3FCeG:ydH;zbZMhSXO|YYm= MorFNwKBkc7:TR?= Mm\OOFghcA>? MUTpcoR2[2W|IEO0MlYmyrFzLkmyKUBieG:ydH;zbZM> M13jZ|I1OjV4NEmx
NCI-H1299/pcDNA3 Ml3JR4VtdCCYaXHibYxqfHliQYPzZZk> Mmn3NE0zOCCwTR?= NVLoZlRjQTZiaB?= M3XO[olvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NGXSN2UzPDF5N{CxNi=>
H1299/ICAM-3 MXHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NE\mVosxNTJyIH7N M1SyXlk3KGh? NHrBXWJqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 M4K5Z|I1OTd5MEGy
NCI-H1299/pcDNA3 NG[3W3JHfW6ldHnvckBCe3OjeR?= NGT6OnMyNzVxMUCvNlDDqG6P MVO5OkBp MlvtbY5lfWOnczDjcIVifmGpZTDv[kBk[XOyYYPld{0{NCB6LDC5MEBidmRiUFHSVC=> MmLNNlQyPzdyMUK=
H1299/ICAM-3 NGDiT3VHfW6ldHnvckBCe3OjeR?= NF:zO4oyNzVxMUCvNlDDqG6P Ml3nPVYhcA>? NXv1cnI5cW6mdXPld{BkdGWjdnHn[UBw\iClYYPwZZNmey1|LDC4MEA6NCCjbnSgVGFTWA>? MVqyOFE4PzBzMh?=
W1 Mn36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LlXWlEPTB;MD6wNFMzKM7:TR?= M2LYZlI1OTRyMUe2
W1VR M1nvemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfxT|BsUUN3ME2wMlA2PiEQvF2= MnfpNlQyPDBzN{[=
K562 NHv5dJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHyS|lKSzVyPUCuNFMzKMLzIECuNFAyKCEQvF2= M4LifFI1OTN3OUO3
K562/ADR MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVWxcVFiUUN3ME2zMlI3OSEEsTCwMlQyOiEQvF2= NHzTSYIzPDF|NUmzOy=>
K562 MnjtRZBweHSxc3nzJGF{e2G7 M1XRXVAvOyEQvF2= MWmyOEBp NYHmUGZEcW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueR?= NFzO[HIzPDF|NUmzOy=>
K562/ADR Ml7kRZBweHSxc3nzJGF{e2G7 NHrsOZk{KM7:TR?= MlHHNlQhcA>? MlHBbY5lfWOnczDhdI9xfG:|aYO= NXP4dGhwOjRzM{W5N|c>
A549 NWLxRmZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTvcJpKSzVyPUCuNVAhyrFiMD6wN{DPxE1? MXOyN|k4OTB5NR?=
K562 NYXHOGpvS2WubDDWbYFjcWyrdImgRZN{[Xl? MXizMlc26oDVNkFCpI5O M{jB[|czyqCqwrC= NES4UW9qdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NXnuUHpuOjN6N{eyNlM>
lucena MkTVR4VtdCCYaXHibYxqfHliQYPzZZk> MmDTN{44PeLCk{[wxsBvVQ>? MYi3NuKhcMLi NFvRe4RvdyCnZn\lZ5Q> MYqyN|g4PzJ{Mx?=
FEPS NVn3NlZHS2WubDDWbYFjcWyrdImgRZN{[Xl? Moi0N{44PeLCk{[wxsBvVQ>? NYXHcFRSPzMEoHlCpC=> NXHDZWM{dm9iZX\m[YN1 MkfJNlM5Pzd{MkO=
A2780 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzkSpBKSzVyPUOuOUBuVQ>? NUK0cVFGOjN6MkmyNFM>
ACHN M3q5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHURWhKSzVyPECuNUBuVQ>? NHnPbmUzOzh{OUKwNy=>
U-937 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRDN2IH7N MoDYNlM5Ojl{MEO=
Jurkat M3LTR2Fxd3C2b4Ppd{BCe3OjeR?= Mlj0OeKh|rypL33sxsA> M4nFVFI1KGh? Mnu3bY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgQ>? NH\SUIszOzhzMESwPS=>
Jurkat M{HTSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7iSVViPcLizsznM41tyqB? MkG2NlQhcA>? NXTqSpRs[XK{ZYP0JGp2emujdDDj[YxteyCrbjDHNk9OKHCqYYPl NF7mbGszOzhzMESwPS=>
Hep-2 MmroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nIUWlEPTB;MD6wOOKyOC5yMTFOwG0> NEPUR4MzOzd6MESyOC=>
Hep-2/v NFrQNXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLrXWpKSzVyPUGuPOKyOC5{MDFOwG0> NWjPepllOjN5OEC0NlQ>
SGC-7901 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWOwMVExKM7:Zz;tcC=> MXKyOE81QC95MjDo NX24Um9icW6qaXLpeJMh[2WubDDndo94fGhiaX6g[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnRibXHucoVz MXGyN|c1OzV5Mh?=
SGC-7901/VCR NGrzOGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4K4U|AuOTBizsznM41t MWiyOE81QC95MjDo MlHSbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy M3j5VFI{PzR|NUey
SGC-7901 MUXBdI9xfG:|aYOgRZN{[Xl? NXXidJZ2cW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueR?= MoO2NlM4PDN3N{K=
SGC-7901/VCR MVfBdI9xfG:|aYOgRZN{[Xl? NFHCRoFqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7 MYiyN|c1OzV5Mh?=
KB-3-1 NYO0[GdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPOTWM2OD1zLk[2JOKyKDBwMU[yJO69VQ>? MWKyN|Y4OzR2NR?=
KB-C2 M361PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moe1TWM2OD1{MEKuOVYhyrFiNEKuOFgyKM7:TR?= NVnU[YxFOjN4N{O0OFU>
KB-3-1 MmLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIG2cXJKSzVyPUGuNlYhyrFiMD6wNlch|ryP M1zF[VI{Pjd|NES1
KB-V1 NIDWSXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TsUGlEPTB;MkC4Mlg2KMLzIEKwMlQh|ryP M2Dkc|I{Pjd|NES1
HEK293/pcDNA3.1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moj1TWM2OD1{ND6xJOKyKDBwMkC0JO69VQ>? M3i4NlI{Pjd|NES1
HEK293/ABCB1 MoXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTN3MUKuPEDDuSB|N{iuN|kyKM7:TR?= MXSyN|Y4OzR2NR?=
A549/EGFP  M1\Ec2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorLNE4xOS1zMECwJO69VQ>? M4nnPWlEPTB;OE[uO{DDuSB{OT6xJO69VQ>? M{mzfFI{PjN2Mkiy
A549/Slug MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWOwMlAyNTFyMECg{txO M3\3e2lEPTB;OT63JOKyKDNwMTFOwG0> NXXLSohFOjN4M{SyPFI>
JFCR39  MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW[xJOK2VQ>? NF3L[HIzPCCq M3XrW2ROW09? NH\odHlu[XKtZXTsfUBqdmO{ZXHz[ZMhfGinIH71cYJmeiCxZjDHNk9OKHCqYYPlJINmdGy| MmjPNlM2QTh{N{[=
A549 MljySpVv[3Srb36gRZN{[Xl? MoLsNVAxKG6P NYD0WXljOTZiaB?= MmTqSG1UVw>? MlnGcIVi\HNidH:gZUBtd3O|IH;mJI1q[3KxdIXieYxmew>? NXH1N5FCOjN3OUiyO|Y>
SGC7901 M2PIVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DuW2lEPTB;MT6yOwKBkcLz4pEJNE4yOSEQvHevcYw> NEnBfIMzOzV4NES4Ni=>
SGC7901/LV-NC M1TDOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXoTWM2OD1zLke35qCKyrIkgJmwMlE3KM7:Zz;tcC=> MV2yN|U3PDR6Mh?=
SGC7901/LV-SGO1 M{XvVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWezWZlwUUN3ME20MlM36oDLwsJihKkxNjN5IN88[{9udA>? NX\oOVNzOjN3NkS0PFI>
SGC7901/VCR M{\GO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjENYFJUUN3M{2yNE42O+LCidMx5qCKOS57NjFOwIcwdWx? NU\GVHV7OjN3NkS0PFI>
SGC7901/VCR-NC M2TuRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTF7Lki25qCKyrIkgJmyMlAyKM7:Zz;tcC=> MkDKNlM2PjR2OEK=
SGC7901/VCR-si-SGO1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTBTWM2OD14LkG45qCKyrIkgJmxMlA{KM7:Zz;tcC=> NUTzWGVUOjN3NkS0PFI>
SGC7901/ADR M3X4UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NISwN4lKSzVyPUeuPFXjiIoEsfMAjVAvPjRizsznM41t NX7CeIVvOjN3NkS0PFI>
SGC7901/ADR-NC MnG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDLephzUUN3ME24Mlk{6oDLwsJihKkxNjZ6IN88[{9udA>? MV6yN|U3PDR6Mh?=
SGC7901/ADR-si-SGO1 NHPDd|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTNwNEdihKnDueLCiUCuNlkh|rypL33s M4LDR|I{PTZ2NEiy
SH-SY5Y  M1v1fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjuOGExOC5yMEGtNVAh|ryP M3Pl[|I1KGh? NEe2OGFKSzVyPUCuNVE{yrFyLkCxNkDPxE1? MkDLNlMyOjlyNkW=
SH-SY5Y  MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjHNE4xODFvMUCg{txO MlnzOFghcA>? M2HTV2lEPTB;MD6wO|jDuTBwMEC5JO69VQ>? NWLXeo9LOjNzMkmwOlU>
SH-SY5Y  M{XHemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXSwMlAxOS1zMDFOwG0> NE\HPVA4OiCq MW\JR|UxRTBwMEWxxtExNjByODFOwG0> Ml3xNlMyOjlyNkW=
SH-SY5Y NHXIRYlCeG:ydH;zbZMhSXO|YYm= NF;PW2ExNjFizszN M1fNeFAuOjRiaB?= NYXseWo1cW6mdXPld{BieG:ydH;zbZMhd2ZiU1itV3k2YSClZXzsd{Bnd2yub4fpcoch[2WubDDjfYNt\SCjcoLld5Qh[XRidHjlJGczN01icHjhd4U> Moq0NlMyOjlyNkW=
SH-SY5Y NV\tWJFwSXCxcITvd4l{KEG|c3H5 M4n0dFAvOSEQvF2= M1;Rb|AuOjRiaB?= NIGw[otqdmS3Y3XzJI1qfG:2aXOgZZJz\XO2wrC= MV[yN|EzQTB4NR?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
MPM2 / Cyclin B1 / Cdc25c / p-Cdc2 / Cdc2 / Aurora B / p-H3 / p-PLK1; 

PubMed: 26156322     


MOLT-4 Cells were treated with vincristine (0.3, 1, and 3 nM) alone or co-treated with SAHA (500 nM) for 24 h. Then, total cell lysates were obtained to evaluate the G2/M phase regulatory protein expression and the tubulin acetylation. Data are expressed as mean values ± SD of at least three separate determinations. S SAHA, V vincristine

26156322
Growth inhibition assay
Cell viability ; 

PubMed: 26156322     


MOLT-4 cells were treated with various concentrations of vincristine for 24 and 48 h, respectively.  Cell viability was measured by MTT assay.

26156322
In vivo Vincristine (3 mg/kg) administrated by a single i.p. injection to mice bearing bilateral subcutaneous xenografts Rh12 or Rh18, induces mean growth delay of >120 and >52 day, and repopulating fractions of 0.06% and 5%, respectively. [6] Vincristine acts on subcutaneous colon 38 tumors in mice by host cell-mediated vascular effects as well as by direct tubulin-mediated cytotoxicity. Vincristine (5 mg/kg) reduces tumor blood flow of tumors by nearly 75% . [7]

Protocol

Cell Research:[1]
- Collapse
  • Cell lines: B16 melanoma cell
  • Concentrations: 10 nM
  • Incubation Time: 3 days
  • Method: Cells are plated in 2 mL of medium in 35-mm plates at a concentration of about 5 × 104 cells/mL and grow for 24 h at 37 ℃ in an atmosphere of 5% CO2 and 95% air. Then medium is replaced with fresh medium lacking or containing 4 nM drug and proliferation is continued for 3 days. Cell counts are done each day in a Coulter Counter after detaching the cells with trypsin and EDTA.
    (Only for Reference)
Animal Research:[6]
- Collapse
  • Animal Models: Human rhabdomyosarcoma xenografts Rh12
  • Formulation: Water solutioin
  • Dosages: 3 mg/kg
  • Administration: A single i.p. administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (108.33 mM)
Water 60 mg/mL (65.0 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 923.04
Formula

C46H58N4O14S

CAS No. 2068-78-2
Storage powder
in solvent
Synonyms Leurocristine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03981510 Recruiting Diagnostic Test: 3D-Transit Constipation|Childhood Acute Lymphoblastic Leukemia|Neurofibromatosis 1|Chronic Constipation With Overflow University of Aarhus June 2019 Not Applicable

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I want to use the product #S1421 for mouse in vivo, could you please give us your advice about administration method?

  • Answer:

    According to the reference cited on our website, we test the solubility of S1421 Staurosporine in 4% DMSO/saline, and it is a suspension at 5 mg/mL. The compound can also be dissolved in the vehicle 4% DMSO/30% PEG 300/10% Tween 80/saline at 5 mg/ml as a clear solution for injection.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Tags: buy Vincristine sulfate | Vincristine sulfate supplier | purchase Vincristine sulfate | Vincristine sulfate cost | Vincristine sulfate manufacturer | order Vincristine sulfate | Vincristine sulfate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID